Governments may onshore part of biopharma supply chain, but it won't be easy: Panel

Singapore

THE Covid-19 pandemic has exposed vulnerabilities in the global biopharmaceutical supply chain, raised renewed concerns over the offshoring of facilities to Asia and highlighted the heavy reliance on large producer markets - such as China and India - for critical medical supplies.

Now, policymakers around the world will thus be compelled to review their supply chain strategy and management so they can ensure supply and mitigate risks.